Enhanced brain immune cells may combat Alzheimer's
Cedars-Sinai researchers boost ACE enzyme in brain immune cells, dramatically reducing Alzheimer's plaques and reversing cognitive decline in mice.| Drug Discovery and Development
The website from which you got to this page is protected by Cloudflare. Email addresses on that page have been hidden in order to keep them from being accessed by malicious bots. You must enable Javascript in your browser in order to decode the e-mail address.| www.drugdiscoverytrends.com
By Ryan N. Phelan | April 28, 2025| Drug Discovery and Development
Stay updated with drug discovery trends on drugdiscoverytrends.com. Dive into pharma and biotech insights, from AI to neurological disease.| Drug Discovery and Development
The one-drug-many-indications model has steadily grown in popularity since the early 2000s. But Irvine, California–headquartered Tarsus Pharmaceuticals is aiming to bring the model to XDEMVY (lotilaner), an antiparasitic drug that first won FDA-approval in dogs. After licensing lotilaner from Elanco, Tarsus won FDA approval for the drug, under the trade name XDEMVY, for the treatment… The post Q2 net sales reach $100M for Tarsus’ XDEMVY, a potential treatment for Lyme and malaria rooted...| Drug Discovery and Development
Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes. GLP-1 receptor agonists mimic gut hormones to curb appetite and slow digestion, a mechanism driving the success of therapies from Novo Nordisk (Ozempic for diabetes and Wegovy for… The post Lilly’s oral GLP-1 drug orforglipron achieves 12.4% weight loss in phase 3 trial bu...| Drug Discovery and Development
Bispecific antibodies (BsAbs) are redefining the landscape of therapeutic design, offering dual-target precision that conventional antibodies can’t match. These specially engineered antibodies bind to either two different antigens or two distinct sites on the same antigen. BsAbs form a powerful new class of therapy which has caused excitement among the drug development community due to… The post Bispecific antibodies: The next generation of precision therapeutics appeared first on Drug ...| Drug Discovery and Development
History’s deadliest infectious disease has a new adversary. Although many think of tuberculosis as a disease of the past, it still kills 1.2 million people annually. Last month, scientists at Texas A&M AgriLife Research published a study in Nature, revealing that they had developed a new compound that could be a tuberculosis treatment breakthrough. The… The post Scientists have discovered a potential new treatment for tuberculosis – even drug-resistant strains appeared first on Drug D...| Drug Discovery and Development
While diagnostic pathologists can review scanned slides remotely with AI assistance and instant global collaboration, much of the clinical trial pathology world still ships physical glass slides between labs, dealing with FedEx delays and proprietary file formats. “For exploratory assays, yes, it’s exploding. Everyone’s enjoying artificial intelligence and machine learning for various aspects, but there’s… The post Digital ready, regulatory waiting: The clinical trial pathology para...| Drug Discovery and Development
Cedars-Sinai researchers boost ACE enzyme in brain immune cells, dramatically reducing Alzheimer's plaques and reversing cognitive decline in mice.| Drug Discovery and Development
AI agents have moved from pilots to practice: 14% of large enterprises report partial or full deployments and 23% are piloting, according to the “Rise of agentic AI” report from Capgemini. But as adoption ticks up, trust in fully autonomous agents slid from 43% to 27% over the past year. What does that mix mean… The post AI agents are proliferating in pharma, but taming them may be the next frontier appeared first on Drug Discovery and Development.| Drug Discovery and Development
Antibiotic resistance is a growing global issue. According to the CDC, antibiotic resistance was associated with almost 5 million deaths in 2019. In the U.S., more than 2.8 million antimicrobial-resistant infections occur annually, killing more than 35,000 people. Researchers at Rockefeller University developed a platform to identify drug resistance genes in the environment before they… The post New technique could help solve the antibiotic resistance problem appeared first on Drug Discov...| Drug Discovery and Development
A study from the Barcelona Institute for Global Health revealed that ivermectin, usually used to treat river blindness and scabies, can reduce malaria transmission. The BOHEMIA trial is the largest study on ivermectin for malaria, and results revealed that the pill reduced malaria by 26%. As mosquitoes become more resistant to insect repellent and other… The post This pill makes blood deadly to mosquitoes and reduced malaria by 26% appeared first on Drug Discovery and Development.| Drug Discovery and Development
Dr. Katie Abouzahr, Johnson & Johnson’s new head of late-stage immunology development, draws on her NHS clinical roots and 11 years at Boston Consulting Group to tackle drug R&D’s most complex challenges. Having recently stepped into the role about a month ago, she oversees a portfolio that includes the newly FDA-approved nipocalimab for myasthenia gravis,… The post J&J bets on nipocalimab and oral peptides in immunology appeared first on Drug Discovery and Development.| Drug Discovery and Development
Eli Lilly and Co. has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion, in a move that bolsters Lilly's push into gene editing for cardiovascular conditions and signals renewed confidence in the sector.| Drug Discovery and Development
Boltz-2, a new open-source model from MIT and Recursion available on GitHub, delivers FEP-class accuracy in about 18 seconds on a single GPU.| Drug Discovery and Development
Scalability is a common issue facing pharma leaders who have deployed Generative AI (GenAI) applications as a proof of concept (PoC). Many are dazzled by their promise of streamlining staid work processes. Agentic AI and other new GenAI technologies can make PoCs faster and easier to launch, advancing scalability as well as security and development… The post Scaling pharma AI PoCs to enterprise deployments: Blending new tech with old-school rigor appeared first on Drug Discovery and Develop...| Drug Discovery and Development
Demand for next-generation GLP-1 drugs is fueling a boom in peptide research, prompting companies like Sai Life Sciences to expand capabilities amid a hot market for obesity and diabetes treatments. “The GLP-1 agonists have exploded the peptide field,” said Maneesh Pingle, Ph.D., executive vice president and head of discovery services at Sai Life Sciences, in… The post Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center appeared first on Drug...| Drug Discovery and Development
Swissmedic has approved Novartis’ Coartem Baby as the first malaria medicine for newborns and young infants, the company announced on Tuesday. The treatment was developed in collaboration with the Medicines for Malaria Venture (MMV). Novartis plans to distribute the treatment on a not-for-profit basis to areas where malaria is endemic. This includes the eight African… The post Swissmedic approves first malaria treatment for infants appeared first on Drug Discovery and Development.| Drug Discovery and Development
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language… The post Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classifi...| Drug Discovery and Development
As in previous years, the 2025 ASCO Annual Meeting showcased a strong portfolio of practice-changing data across a wide range of tumor types. Combination therapies remain a central theme, continuing to drive meaningful improvements in clinical outcomes. These benefits are increasingly balanced by evolving strategies for managing adverse events, underscoring the field’s commitment to both… The post New treatment paradigms in oncology: Highlights from the ASCO 2025 annual meeting appeared f...| Drug Discovery and Development
Several leading medical organizations filed a lawsuit against Robert F. Kennedy Jr. on Monday, claiming that recent decisions to stop recommending vaccines to pregnant women and children are unscientific and harmful to the public. The suit was filed in the U.S. District Court for the District of Massachusetts. The American Public Health Association (APHA), the… The post Six leading medical organizations sue RFK Jr. over vaccine recommendations appeared first on Drug Discovery and Development.| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
By Edward Pryor | June 17, 2025| Drug Discovery and Development
By Brian Buntz | June 25, 2025| Drug Discovery and Development
Researchers at the Korea Research Institute of Standards and Science (KRISS) have created a new nanomaterial that can simultaneously detect and treat cancer using multiple approaches. In laboratory tests with mice, the gold-iron particles enabled real-time tumor imaging while delivering targeted treatment through heat, chemical reactions and immune system activation. Published in the Chemical Engineering… The post Korean team reports all-in-one cancer nanomedicine in pre-clinical studies ap...| Drug Discovery and Development
KEY TAKEAWAYS: Regeneron (#20 by revenue in FY2024) became the third company to launch a BCMAxCD3 bispecific for myeloma, following J&J (#3) and Pfizer (#2). Company spends 36.1% of revenue on R&D—highest in pharma—growing at 19.5% annually Patent portfolio shows 652 antibody patents (50.3% of total) with 31 bispecific-specific filings Tarrytown, New York–based Regeneron may… The post Why Regeneron’s Lynozyfic FDA approval validates its extreme R&D thesis appeared first on Drug Disc...| Drug Discovery and Development
From the Grateful Dead’s tour bus to the FDA’s approval queue, from “turn on, tune in, drop out” to potentially “take two doses and see me in a year,” this is the improbable journey of psychedelics in 2025. We now live in a world where a ketamine analog marketed by Johnson & Johnson could provide… The post Why Cybin’s CEO sees RFK Jr. and J&J’s ketamine clinics as keys to clinical psilocybin’s mainstream moment appeared first on Drug Discovery and Development.| Drug Discovery and Development
Two weeks ago, Robert F. Kennedy fired all 17 members of the ACIP and quickly appointed eight new members. On Tuesday, the New York Times reported that Michael Ross withdrew from the committee, leaving the ACIP with seven remaining members. The new advisory committee on immunization practices had its first meeting yesterday. Walking back flu… The post RFK’s new ACIP changed longstanding vaccine recommendations appeared first on Drug Discovery and Development.| Drug Discovery and Development
Genmab, a Danish company focused on developing antibody therapies for patients with cancer, opened a new site in Plainsboro, NJ. The company was awarded $8.4 million in tax credits over seven years by the Murphy Administration to develop the new location. Expanding presence in NJ “Our extension at the Princeton Forrestal Center will strengthen our… The post As some biotechs cut, Genmab unveils striking new site near Princeton appeared first on Drug Discovery and Development.| Drug Discovery and Development
OS Therapies announced it has received positive written feedback from the U.S. Food and Drug Administration (FDA) following a mid-June Type D meeting. The development supports its plan to use an external control arm to support a Biologics Licensing Application (BLA) for its lead candidate, OST-HER2, a Listeria monocytogenes-based immuno-oncology asset originally developed by Advaxis… The post OS Therapies announces favorable FDA feedback on external control arm strategy for osteosarcoma dru...| Drug Discovery and Development
Nektar Therapeutics stock skyrocketed 287% after rezpegaldesleukin hit all endpoints in atopic dermatitis trials, but ongoing litigation with Lilly could complicate matters.| Drug Discovery and Development
Dupixent (dupilumab) has been approved by the FDA for the treatment of adult patients with bullous pemphigoid.| Drug Discovery and Development
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
By Brian Buntz | January 21, 2025| Drug Discovery and Development
By Brian Buntz | May 30, 2025| Drug Discovery and Development
By Julia Rock-Torcivia | June 20, 2025| Drug Discovery and Development
By Brian Buntz | June 17, 2025| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
Cambridge-based biotechnology company Parallel Bio has closed a $21 million Series A funding round led by AIX Ventures.| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
Sanofi and Regeneron have announced that the monoclonal antibody outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints in a phase 4 study focused on patients with chronic rhinosinusitis.| Drug Discovery and Development
The FDA has approved zoliflodacin for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older.| Drug Discovery and Development
The FDA has approved ENFLONSIA for the prevention of RSV lower respiratory tract disease in infants and newborns.| Drug Discovery and Development
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
Labcorp rolls out new NGS panels, HRD testing, and a Leica-Proscia digital pathology platform to accelerate biomarker screening.| Drug Discovery and Development
From accelerating drug discovery and optimizing clinical trials to automating regulatory documentation and improving patient engagement, AI offers opportunities to improve efficiency, reduce costs, and bring therapies to market faster.| Drug Discovery and Development
The once pioneering DNA test company 23andMe is now a penny stock that has filed for bankruptcy. Its CEO Anne Wojcicki is also stepping down.| Drug Discovery and Development
They are highly effective at suppressing inflammation and the reducing the activity of the body’s immune system, providing rapid relief from associated symptoms.| Drug Discovery and Development
By Brian Buntz | February 19, 2025| Drug Discovery and Development
By Brian Buntz | April 30, 2025| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
AnaptysBio’s investigational drug rosnilimab has delivered promising Phase 2b trial results for moderate-to-severe rheumatoid arthritis.| Drug Discovery and Development
Capturing complete, consistent, and contextualized data is vital in AI/ML, especially within the biopharma industry.| Drug Discovery and Development
$1B women's health push and RNAi advances mark JPM 2025, with solid tumor therapies gaining momentum| Drug Discovery and Development
Novo Nordisk continues to face supply shortages for its Wegovy (semaglutide) pens, which are FDA approved for weight management.| Drug Discovery and Development
